ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ars Pharmaceuticals, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.096 Good morning and welcome to the ARS Pharmaceuticals Conference Call. 00:00:03.096 -- 00:00:05.720 At this time, all participants are in a listen-only mode. 00:00:05.720 -- 00:00:08.565 After the company's prepared remarks, we'll open the line for questions. 00:00:08.565 -- 00:00:11.169 Please be advised today's conference is being recorded. 00:00:11.169 -- 00:00:13.673 I'll now turn the call over to Justin Chakpa, Chief Business Officer. 00:00:13.673 -- 00:00:16.073 Please go ahead. 00:00:17.379 -- 00:00:22.747 Good morning and thank you for joining our second quarter 2025 earnings conference call. 00:00:22.747 -- 00:00:26.613 This morning, we issued a press release detailing our financial results and commercial 00:00:26.613 -- 00:00:33.482 highlights. which is available in the investors and media section of our website at ars-pharma.com. 00:00:34.066 -- 00:00:38.953 With me on the call are Richard Lowenthal, our co-founder, president, and CEO, who will 00:00:38.953 -- 00:00:42.017 review recent corporate updates and achievements. 00:00:42.017 -- 00:00:47.905 Eric Perez, our chief commercial officer, will cover our commercial activities and progress. 00:00:47.905 -- 00:00:52.932 And Kathy Scott, our CFO, who will provide a summary of our financial results and 00:00:52.932 -- 00:00:54.790 cash positions. 00:00:54.790 -- 00:00:59.475 Before we begin, please note that today's remarks may contain forward-looking statements. 00:00:59.475 -- 00:01:04.801 Actual results may differ materially. Please refer to our earnings release and SEC filings 00:01:04.801 -- 00:01:07.023 for further risk disclosures. 00:01:07.023 -- 00:01:09.666 With that, I'll turn the call over to Rich. 00:01:09.666 -- 00:01:13.911 Thank you, Justin. Good morning, eve...